“A Case Report Overwhelming Response to TNF-Alfa Inhibitor Infliximab “innovator” Vs. Adalimumab ‘Bio-similar’ in a Previously Therapy Naive Adult”. 2022. Indian Journal of Case Reports 8 (3): 58-61. https://doi.org/10.32677/ijcr.v8i3.3317.